Mode
Text Size
Log in / Sign up
N/A N=106

Follow-up of Post-spinal Implantable Neurostimulator PRECISION®

Chronic Refractory Neuropathic Pain · Ischemic Peripheral Pain

Enrolled (actual)
106
Serious AEs
21.7%
Results posted
Nov 2019
Primary outcome: Primary: Percentage of Implanted Patients (de Novo Implants) With an Improvement of at Least 50% of the Overall Average Pain Over the Last 8 Days, Evaluated by Numerical Scale at the First Follow-up Visit, at 1 Year, and 2 Years. — 34.5; 35.7 percentage of patients

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Neurostimulator Precision (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Cemka-Eval
Primary completion
Dec 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Implanted Patients (de Novo Implants) With an Improvement of at Least 50% of the Overall Average Pain Over the Last 8 Days, Evaluated by Numerical Scale at the First Follow-up Visit, at 1 Year, and 2 Years.
34.5; 35.7
PRIMARY
Average Pain Score Over the Last 8 Days, Evaluated by Numerical Scale at 1 Year, and at 2 Years.
4.5; 4.9
SECONDARY
Percentage of Implanted Patients (de Novo Implants) With an Improvement of at Least 30% of the Overall Average Pain, Evaluated by Numerical Scale
53.7; 53.6; 54.5; 51.4; 46.3; 40.6
SECONDARY
Patients' Opinion on the Evolution of Pain
49; 55
SECONDARY
Evolution of the Use of Other Pain Treatments
42; 54
SECONDARY
Evolution of Quality of Life (SF-12) - Physical Score
30; 38
SECONDARY
Patients' Willingness to Restart the Treatment
45; 57
SECONDARY
Percentage of Patients With Anxiety and Depression Disorders
38.9; 45.6
SECONDARY
Evolution of Quality of Life (SF-12) - Mental Score
16; 17
SECONDARY
Evolution of the Use of Level 3 Analgesics
67.9; 55.6

Summary

Assessing the long-term efficacy, complications, revision rates and final explantation of the device

Eligibility Criteria

Inclusion Criteria

  • Adult patient receiving spinal implantation of a neurostimulator PRECISION ® ( primary implantation or reimplantation)

Exclusion Criteria

  • Refusal of patient
  • Patient whose long-term monitoring will not be possible
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02208999). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search